Zosano Pharma ( ) - 株価, ニュースと分析OTCPK:ZSAN.Q

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

ZSAN.Q 株式概要

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system.

会社概要

ZSAN.Q ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

リスク分析

Has less than 1 year of cash runway

Does not have a meaningful market cap ($3K)

Earnings have declined by 5% per year over past 5 years

Makes less than USD$1m in revenue ($659K)

+3 さらなるリスク

Zosano Pharma Corporation 競合他社

Lucira Health

OTCPK:LHDX.Q

US$4.2k

Viveve Medical

OTCPK:VIVE

US$5.4k

ViewRay

OTCPK:VRAY.Q

US$18.3k

American Bio Medica

OTCPK:ABMC

US$4.8k

価格と性能

の歴代最高値、変動、値下がりまとめZosano Pharma
過去の株価
現在の株価	US$0.0007
52週高値	US$24.80
52週安値	US$0.0001
ベータ	2.73
11ヶ月の変化	133.33%
3ヶ月変化	-99.45%
1年変化	-100.00%
33年間の変化	-100.00%
5年間の変化	-100.00%
IPOからの変化	-100.00%

Recent updates

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Nov 02

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Jun 29

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

May 26

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Apr 30

Zosano shares rise on migraine treatment NDA resubmission update

Apr 26

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Mar 15

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

Feb 01

Zosano Pharma requests FDA meeting for its Qtrypta application

Jan 04

Zosano Pharma EPS misses by $0.01

Nov 13

株主還元

	ZSAN.Q	US Medical Equipment	US 市場
7D	40.0%	2.9%	0.8%
1Y	-100.0%	30.4%	38.4%

業界別リターン: ZSAN.Q underperformed the US Medical Equipment industry which returned -22.2% over the past year.

リターン対市場: ZSAN.Q underperformed the US Market which returned -20.2% over the past year.

価格変動

Is ZSAN.Q's price volatile compared to industry and market?
ZSAN.Q volatility
ZSAN.Q Average Weekly Movement	4,827.6%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.2%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.0%

安定した株価: ZSAN.Q's share price has been volatile over the past 3 months.

時間の経過による変動: ZSAN.Q's weekly volatility has increased from 2395% to 4789% over the past year.

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
2006	40	Steven Lo	www.zosanopharma.com

Zosano Pharma Corporation 基礎のまとめ

Zosano Pharma の収益と売上を時価総額と比較するとどうか。
ZSAN.Q 基礎統計学
時価総額	US$3.43k
収益（TTM）	-US$55.19m
売上高(TTM)	US$659.00k

0.0x

P/Sレシオ

0.0x

PER（株価収益率

ZSAN.Q は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
ZSAN.Q 損益計算書（TTM）
収益	US$659.00k
売上原価	US$20.85m
売上総利益	-US$20.19m
その他の費用	US$35.01m
収益	-US$55.19m

直近の収益報告

Mar 31, 2022

次回決算日

該当なし

一株当たり利益（EPS）	-11.26
グロス・マージン	-3,063.13%
純利益率	-8,375.11%
有利子負債／自己資本比率	0%

ZSAN.Q の長期的なパフォーマンスは？

過去の実績と比較を見る

This company is no longer active

ZSAN.Q 株式概要

報酬

リスク分析

Zosano Pharma Corporation 競合他社

OTCPK:LHDX.Q

US$4.2k

OTCPK:VIVE

US$5.4k

OTCPK:VRAY.Q

US$18.3k

OTCPK:ABMC

US$4.8k

価格と性能

最新ニュース

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Recent updates

Emergex USA Corporation completed the acquisition of Substantially all assets of Zosano Pharma Corporation for $1 million.

Emergex USA Corp. agreed to acquire Substantially all assets of Zosano Pharma Corporation (OTCPK:ZSAN.Q) for $1.3 million.

Motion for Case Conversion Filed for Zosano Pharma Corporation

Motion for Asset Sale Filed by Zosano Pharma Corporation

Zosano Pharma Corporation to Delist from Nasdaq

Zosano Pharma Corporation Filed for Bankruptcy

Joseph “Jay” P. Hagan Resigns as Director of the Board of Directors of Zosano Pharma Corporation

Zosano Pharma Corporation Reports Impairment Charges for the First Quarter Ended March 31, 2022

Consensus forecasts updated

Steven A. Elms Tenders His Resignation as Director of the Board of Directors of Zosano Pharma Corporation

Price target decreased to US$21.00

Consensus revenue estimates increase by 95%

Zosano Pharma Corporation Receives a Response Letter from the U.S. Food and Drug Administration with Regard to the Company’s January 18, 2022 Resubmission of the 505(b)(2) New Drug Application for M207

Zosano Pharma Corporation has completed a Composite Units Offering in the amount of $15.375 million.

Zosano Pharma Corporation has completed a Composite Units Offering.

Zosano Pharma Corporation Resubmits its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) New Drug Application to the U.S. Food and Drug Administration

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of A Trivalent Influenza Vaccine Formulated on Its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine At A Higher Dose

Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?

Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?

Consensus forecasts updated

Consensus revenue estimates increase to US$2.08m

Zosano Pharma Corporation Announces Publication of Clinical Data Regarding the Long-Term Use of Qtrypta for the Treatment of Acute Migraine in the Journal of Headache and Pain

Data supports long-term benefit of Zosano's migraine candidate; shares surge 23%

Consensus forecasts updated

Zosano Pharma: Early PK+Safety Study In Q3 2021 May Breathe New Life Into This Biotech

Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study Following Protocol Review by FDA

Zosano shares rise on migraine treatment NDA resubmission update

Consensus revenue estimates increase to US$5.17m

Auditors Have Doubts About Zosano Pharma (NASDAQ:ZSAN)

Earnings miss expectations

Zosano Pharma Corporation Announces John Walker, Chairman of the Board of Directors to Retire from the Board

Zosano Pharma Confirms NDA Resubmission Strategy Following Type A Meeting Minutes from FDA

New 90-day high: US$1.93

Zosano Pharma Corporation Announces NDA Resubmission Plans Following Type A Meeting with FDA

Zosano Pharma up 21% following FDA feedback on Qtrypta application; presents Qtrypta data in migraine

New 90-day high: US$0.81

Zosano Pharma Requests Type A Meeting with the Fda to Review Resubmission Plans for Qtrypta™ New Drug Application

Zosano Pharma requests FDA meeting for its Qtrypta application

Bragar Eagel & Squire, P.C. Reminds Investors of Class Action Lawsuit Filed Against Zosano Pharma Corporation

Pomerantz LLP Reminds Shareholders with Losses on Their Investment in Zosano Pharma Corporation of Class Action Lawsuit and Upcoming Deadline

Zosano Pharma EPS misses by $0.01

New 90-day low: US$0.36

Rosen Announces Filing of Securities Class Action Lawsuit Against Zosano Pharma Corporation

Price target lowered to US$2.00

New 90-day low: US$0.64

New 90-day low: US$0.70

Zosano Pharma Corporation Receives Discipline Review Letter from the U.S. Food and Drug Administration in Connection with the Qtrypta

Zosano Pharma Corporation has completed a Follow-on Equity Offering in the amount of $20.782018 million.

New 90-day high - US$1.69

New 90-day high - US$1.22

Zosano Pharma Corporation(NasdaqCM:ZSAN) dropped from Russell Microcap Growth Index

株主還元

価格変動

会社概要

Zosano Pharma Corporation 基礎のまとめ

0.0x

0.0x

収益と収入